{"Symbol": "GALT", "AssetType": "Common Stock", "Name": "Galectin Therapeutics, Inc", "Description": "Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071", "FullTimeEmployees": "4", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "155158864", "EBITDA": "None", "PERatio": "None", "PEGRatio": "0", "BookValue": "0.609", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-0.418", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.235", "ReturnOnEquityTTM": "-0.3969", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "-0.312", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "8", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "0", "PriceToBookRatio": "4.5469", "EVToRevenue": "0", "EVToEBITDA": "0", "Beta": "2.4115", "52WeekHigh": "4.5", "52WeekLow": "1.5", "50DayMovingAverage": "2.7778", "200DayMovingAverage": "2.5106", "SharesOutstanding": "57029200", "SharesFloat": "41107944", "SharesShort": "5546871", "SharesShortPriorMonth": "5464661", "ShortRatio": "32.04", "ShortPercentOutstanding": "0.09", "ShortPercentFloat": "0.1758", "PercentInsiders": "28.339", "PercentInstitutions": "17.467", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "1:6", "LastSplitDate": "2012-03-23"}